Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019064312) TETRAVALENT DENGUE VACCINE AND PROCESSES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/064312 International Application No.: PCT/IN2018/050352
Publication Date: 04.04.2019 International Filing Date: 01.06.2018
IPC:
A61K 39/12 (2006.01) ,C07K 14/005 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
12
Viral antigens
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005
from viruses
01
DNA viruses
03
Herpetoviridae, e.g. pseudorabies virus
05
Epstein-Barr virus
Applicants:
INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY [IN/IN]; Aruna Asaf Ali Marg New Delhi 110067, IN
Inventors:
RAJPOOT, Ravi Kant; IN
SHUKLA, Rahul; IN
ARORA, Upasana; IN
KHANNA, Navin; IN
Agent:
ADASTRA IP; B2-1050-Spaze iTech Park Sohna Road Delhi-NCR Gurgaon 122002, IN
Priority Data:
20171103462629.09.2017IN
Title (EN) TETRAVALENT DENGUE VACCINE AND PROCESSES THEREOF
(FR) VACCIN TÉTRAVALENT CONTRE LA DENGUE ET PROCÉDÉS ASSOCIÉS
Abstract:
(EN) A recombinant dengue virus Envelope (E) protein based tetravalent mosaic virus- like particle vaccine comprising E proteins of the DENV -1, -2, -3 and -4 serotypes co-expressed in a single P. pastoris clone that co-assemble to form VLPs. A method for producing a recombinant tetravalent virus-like particle (VLP) vaccine against DENV -1, -2, -3 and -4 serotypes, the method comprising: preparing a plasmid harbouring a tandem assembly of independent expression cassettes of DENV-1, -2, -3 and -4 E genes; electroporating the plasmid into yeast cells pre-treated with lithium acetate- DTT solution.
(FR) L'invention concerne un vaccin tétravalent recombiné de pseudo-particules virales mosaïques, à base de protéine d'enveloppe (E) du virus de la dengue, comprenant des protéines E des sérotypes DENV-1, -2, -3 et -4 co-exprimés dans un clone P. pastoris unique qui les co-assemble pour former des pseudo-particules virales (VLP). L'invention concerne également un procédé de production d'un vaccin tétravalent recombiné de pseudo-particules virales (VLP) contre les sérotypes DENV-1, -2, -3 et -4, ce procédé consistant : à préparer un plasmide abritant un ensemble en tandem de cassettes d'expression indépendantes de gènes E de DENV-1, -2, -3 et -4 ; et à réaliser l'électroporation du plasmide dans des cellules de levure pré-traitées avec une solution d'acétate de lithium-DTT.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)